MELBOURNE, Australia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be participating in a fireside ...
Immuron’s financial position remains solid, giving it a long cash runway for its ongoing clinical trials. including the Phase 2 trial of Travelan® and the development of IMM-529, without immediate ...
with enterotoxigenic Escherichia coli (ETEC) playing a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with ...